Across the country, telehealth use has spiked as providers offer virtual patient visits to ensure medical needs are met while minimizing COVID-19 exposure. Regulatory agencies have loosened some restrictions on telehealth during this crisis, and more and more payers have begun to reimburse for it as they would for any other medical service.
In the experiments, the lead antiviral candidate, named LCB1, rivaled the best-known SARS-CoV-2 neutralizing antibodies in its protective actions. LCB1 is currently being evaluated in rodents.
The systematic review, published in Lancet Digital Health, shows that evidence around the effectiveness of automated contact tracing systems is currently very limited, and
"Traditional public health surveillance lacks the agility to provide on-demand insights. As a result, when public leaders need real time data to inform their responses to COVID-19's mental health burdens, all that can be mustered is theoretical speculation," said Dr. John W. Ayers who specializes in monitoring the health needs of the public.